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Abstract 1 
Lactobacilli contain different cell envelope proteinases (CEPs) responsible for the 2 
hydrolysis of caseins and the release of various bioactive peptides. In this work, we explored the 3 
CEP activity of Lactobacillus casei PRA205 and Lactobacillus rhamnosus PRA331 whole cells 4 
towards β-, αS1-, κ- and αS2-caseins in bovine milk. Mass spectrometry analysis of fermented milk 5 
hydrolysates identified a total of 331 peptides, which were mainly derived from β-caseins (59.0 and 6 
60.1% for PRA205 and PRA331, respectively). The analysis of αS1-casein (f1-23) cleavage site 7 
specificity congruently supports that Lb. casei PRA205 and Lb. rhamnosus PRA331 exhibited a 8 
mixed-type CEPI/III activity. PRA205 and PRA331 CEPs also showed cleavage site specificity 9 
toward β-casein, preferentially. These CEPs cleaved the peptide bond preferentially when 10 
hydrophobic or negatively charged amino acids were present. 13.5% and 13.7% of peptides released 11 
by Lb. casei PRA205 and Lb. rhamnosus PRA331 CEPs were found to have 100% homology with 12 
previously identified bioactive peptides.  13 
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1. Introduction 14 
Food intake with the goal of improving human health is an ongoing focus for research. 15 
Recommendations for the consumption of certain nutritious fermented foods date back to the 16 
Hippocratic Corpus of Ancient Greece. The idea that lactic acid bacteria (LAB) fermenting milk are 17 
responsible for enhancing health and delaying the human aging was first proposed by the Russian 18 
scientist Elie Metchnikoff more than a century ago (Mackowiak, 2013). In the past years, research 19 
has documented a wide range of health benefits exerted by dairy LAB, especially immune and 20 
metabolic ones, and it is now focusing to decipher the microbial mechanisms underpinning these 21 
health-promoting effects (Reid, 2015). 22 
Some beneficial effects exerted by LAB are due to the generation of secondary metabolites 23 
with health-promoting properties. The most important biogenic compounds in fermented milk are 24 
the bioactive peptides released from caseins via the LAB proteolytic system. Biological activities 25 
associated with such peptides include immunomodulatory, antibacterial, anti-hypertensive, 26 
antioxidant, mineral binding, and opioid-like properties (Brown et al., 2017). In addition, dairy 27 
LAB are auxotrophic for many amino acids and efficient casein breakdown is crucial to make LAB 28 
competitive as dairy starters (S-LAB), as well as suitable to survive in ripened cheeses as non-29 
starter LAB (NS-LAB) (Kunji, Mierau, Hagting, Poolman, & Konings, 1996). The amino acid 30 
release also contributes to the aroma compound formation during cheese ripening and impacts 31 
sensorial properties and consumer’s acceptance of dairy foods (McSweeney & Sousa, 2000). 32 
Cell envelope proteinases (CEPs) are large multi-domain proteins anchored to the cell wall 33 
that catalyse the first step of hydrolysis of milk caseins into peptides. Different transport systems 34 
then internalize these peptides into the cell, where they are further hydrolysed by numerous 35 
intracellular peptidases (Savijoki, Ingmer, & Varmanen, 2006). Six different types of CEPs have 36 
been described in several LAB species: PrtB from Lactobacillus delbrueckii subsp. bulgaricus 37 
(Laloi, Atlan, Blanc, Gilbert, & Portalier, 1991); PrtH from Lactobacillus helveticus (Genay, Sadat, 38 
Gagnaire & Lortal, 2009); PrtL from Lactobacillus delbrueckii subsp. lactis (Villegas, Brown, 39 
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Savoy de Giori, & Hebert, 2015); PrtP from Lactococcus lactis (Kok, Leenhouts, Haandrikman, 40 
Ledeboer, & Venema, 1988), Lactobacillus paracasei (Holck & Naes, 1992), Lactobacillus casei 41 
(Fernández de Palencia, Peláez, Romero, & Martín-Hernández, 1997; Kojic, Fira, Banina, & 42 
Topisirovic, 1991), Lactobacillus rhamnosus (Guo et al., 2016) and Lactobacillus plantarum 43 
(Strahinic, Kojic, Tolinacki, Fira, & Topisirovic 2010); PrtR from Lactobacillus rhamnosus (Pastar 44 
et al., 2003); and PrtS from Streptococcus thermophilus (Siezen, 1999). These proteinases vary in 45 
substrate specificity, domain composition and cell wall anchoring, but all of them belong to the so-46 
called subtilase family as they contain the catalytic serine protease domain showing sequence 47 
homology to the active site of subtilases (Savijoki et al., 2006; Sadat-Mekmene, Genay, Atlan, 48 
Lortal, & Gagnaire, 2011a). Most frequently, LAB possess only one CEP, but the presence of two 49 
CEPs has been described in lactobacilli (Sadat-Mekmene et al., 2011b). 50 
Much of the current knowledge on LAB proteolytic system comes from studies on S-LAB 51 
species, such as Lc. lactis, Lb. delbrueckii subsp. bulgaricus and Lb. helveticus and only few works 52 
has been done to elucidate the role of NS-LAB. Recently, the NS-LAB species Lb. paracasei, Lb. 53 
casei and Lb. rhamnosus were proven to generate bioactive casein-derived peptides during milk 54 
fermentation (Guo et al., 2016; Solieri, Rutella, & Tagliazucchi, 2015). Lb. casei/Lb. paracasei 55 
PrtP-encoded CEP was also demonstrated to degrade pro-inflammatory chemokines associated to 56 
inflammatory bowel diseases (Hormannsperger, von Schillde, & Haller, 2013). Consequently, there 57 
is an increasing interest to study NS-LAB proteases responsible for the release of bioactive peptides 58 
(Lozo et al., 2011). 59 
In our previous work, we demonstrated that two mesophilic NS-LAB strains isolated from 60 
Parmigiano Reggiano ripened cheese, namely Lb. casei PRA205 and Lb. rhamnosus PRA331, 61 
exhibit safety and technological performance compatible with probiotic properties (Solieri, Bianchi, 62 
Mottolese, Lemmetti, & Giudici, 2014). They also release the angiotensin-I-converting enzyme 63 
(ACE)-inhibiting peptides Valine-Proline-Proline (VPP) and Isoleucine-Proline-Proline (IPP) from 64 
caseins at doses that may exert antihypertensive effects in vivo (Solieri et al., 2015). Despite these 65 
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multiple interesting properties, the activity and specificity of CEPs from strains PRA205 and 66 
PRA331 remain unknown, as well as their potential to release additional milk-derived peptides 67 
other than VPP and IPP. The aim of this work was to fill this gap and to evaluate the pattern of 68 
casein breakdown by PRA205 and PRA331 whole cells CEP activities through a peptidomic 69 
approach. 70 
2. Materials and Methods 71 
2.1 Microorganisms, media and growth conditions 72 
Lactobacillus casei PRA205 and Lb. rhamnosus PRA331 were isolated from ripened 73 
Parmigiano Reggiano cheese (Solieri, Bianchi, & Giudici, 2012) and deposited in Unimore 74 
Microbial Culture Collection (www.umcc.unimore.it) for long-term preservation. The cultures were 75 
activated from their frozen forms (stored in MRS medium supplemented with 25% (v/v) glycerol at 76 
−80°C) by transferring them in MRS broth and incubating at 37°C for 24h under anaerobic 77 
conditions. After two rounds of growth on the same medium, strains were routinely maintained on 78 
MRS medium supplemented with 7% (w/v) agar at 4°C for the duration of the experiments. 79 
2.2 Inoculum preparation and milk fermentation  80 
Milk fermentation trials were carried out in triplicate as follows. Single-colony cultures were 81 
inoculated in MRS broth for 24h at 37°C. Cells were washed twice with 50 mmol L-1 Tris-HCl 82 
buffer (pH 6.5), re-suspended in 10% (w/w) skimmed milk and used as pre-cultures (2% v/v) to 83 
inoculate milk batches prepared with 50 mL of ultra-high temperature-treated (UHT) skimmed 84 
bovine milk. Fermentation was carried out for 72h at 37°C at 10 rpm. pH values were determined 85 
over time as previously reported (Solieri et al., 2015). At the end of the fermentation (pH values ≤ 86 
4.0 for at least two consecutive measurements), samples were taken to estimate milk protein 87 
hydrolysis, ACE-inhibitory and radical scavenging activities as reported in section 2.4.  88 
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2.3 Cell viability assay 89 
PRA205 and PRA331 cells were harvested by centrifugation after 24, 48 and 72h of milk 90 
fermentation, twice washed with physiological solution (9 g L-1 NaCl) and re-suspended at the final 91 
concentration of 107 CFU mL-1, according to the correlation curves between OD600nm and CFU 92 
values previously established for every strain (Rutella, Tagliazucchi, & Solieri, 2016). Bacterial 93 
suspensions were stained with LIVE/DEAD BacLight Bacterial Viability Kit (Invitrogen) and 94 
live/dead cell ratio was measured according to manufacture instructions. Fluorescence intensity was 95 
measured with a Jasco FP-6200 spectrofluorometer (Jasco, Orlando FL, U.S.A.). 96 
2.4 Determination of milk protein hydrolysis, radical scavenging and angiotensin I-converting 97 
enzyme (ACE)-inhibitory activities 98 
Milk protein hydrolysis and radical scavenging activity were determined on the TCA-99 
soluble supernatants (peptidic fractions) obtained by treating fermented milk with 1% (w/v) TCA 100 
followed by a centrifugation at 10,000g for 20 min (4°C). In particular, milk protein hydrolysis was 101 
determined by measuring the amounts of released amino groups using the 2,4,6-102 
trinitrobenzenesulfonic acid (TNBS) assay (Adler-Nissen, 1979). Briefly, 50 μL of appropriately 103 
diluted peptidic fractions were mixed with 400 µL of sodium phosphate buffer (0.1 mmol L-1; pH 104 
8.2) and 400 µL of 0.1% TNBS solution (prepared in the same sodium phosphate buffer). After 60 105 
min of incubation at 50°C, the reactions were stopped by adding 800 µL of HCl 0.1 mmol L-1. The 106 
absorbance values at 340 nm were read using a Jasco V-550 UV/Vis spectrophotometer (Jasco, 107 
Orlando, FL, USA.). A calibration curve was prepared using leucine as standard (range 0.1-2.0 108 
mmol L-1) and the results were expressed as mmol L-1 of leucine equivalents. 109 
The antioxidant activity of the peptidic fractions was measured as radical scavenging 110 
activity using the ABTS radical cation decolourization assay (Re et al., 1999) and expressed as mg 111 
L-1 of Trolox. 112 
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ACE-inhibitory (ACEi) activity was determined according to Ronca-Testoni (1983) on the 113 
ultra-filtrated fraction obtained from fermented milk as previously reported (Solieri et al., 2015). 114 
The tripeptide 2-furanacryloyl–phenylalanylglycylglycine (FAPGG) was used as substrate assay 115 
and the ACEi activity was calculated as percent of inhibition (ACEi%). 116 
Three analytical replicates were run for each sample collected at the end of each 117 
fermentation trial (carried out in triplicate) in all the assays. 118 
2.5 Determination of peptides with nanoflow LC-ESI-QTOF MS analysis  119 
Peptidomic analysis was performed by injecting the TCA-soluble supernatant of fermented 120 
milk on a 1200 Series Liquid Chromatographic two-dimensional system coupled to a 6520 121 
Accurate-Mass QTOF LC/MS via a Chip Cube Interface (Agilent Technologies, Santa Clara, CA, 122 
USA) as described in Tagliazucchi, Helal, Verzelloni, Bellesia, & Conte (2016). Chromatographic 123 
separation was performed on a ProtID-Chip-43(II) including a 4 mm 40 nL enrichment column and 124 
a 43 mm × 75 μm analytical column, both packed with a Zorbax 300SB 5 μm C18 phase (Agilent 125 
Technologies). The mobile phase consisted of (A) H2O/acetonitrile/formic acid (96.9:3:0.1, v/v/v) 126 
and (B) acetonitrile/H2O/formic acid (94.9:5:0.1, v/v/v). The sample (2 μL) was loaded onto the 127 
Chip enrichment column at a flow rate of 4 μL min-1 with a mobile phase consisting of 100% A 128 
using a G1376A capillary pump. A flush volume of 2 μL and a flush-out factor of 5 were used. 129 
After valve switching, a gradient elution was performed throughout the enrichment and analytical 130 
columns at 500 nL min-1 using a G2226A nano pump. The gradient started at 0% B for 1 min, and 131 
then linearly ramped up to 90% B in 70 min. The mobile phase composition was maintained at 90% 132 
B for 15 min in order to wash both enrichment and analytical columns. The mass spectrometer was 133 
tuned and calibrated according to the manufacturer's instructions in extended dynamic range (2 134 
GHz) mode as reported by Dei Più et al. (2014). 135 
For peptide identification, MS/MS spectra were converted to .mgf files and were then 136 
searched against the Swiss-Prot database using Protein Prospector (http://prospector.ucsf.edu) and 137 
8 
 
MASCOT (Matrix Science, Boston, MA, USA) protein identification softwares. The following 138 
parameters were considered: enzyme, none; peptide mass tolerance, ± 40 ppm; fragment mass 139 
tolerance, ± 0.12 Da; variable modification, oxidation (M) and phosphorylation (ST); maximal 140 
number of post-translational modifications permitted in a single peptide, 4. We considered only 141 
peptides with a best expected value lower than 0.05 that corresponded to P<0.01. The assignment 142 
process was complemented and validated by the manual inspection of MS/MS spectra. Three 143 
replicates for each fermentation trial was injected in the mass spectrometer and only the peptides 144 
present in at least two replicates were considered significant and included in the analysis. 145 
2.6 Identification of bioactive peptides 146 
The identified peptides in milk samples were investigated for literature-identified bioactive peptides 147 
using the BIOPEP database and the Milk Bioactive Peptide Database (MBPDB) (Minkiewicz, 148 
Dziuba, Iwaniak, Dziuba, & Darewicz, 2008; Nielsen, Beverly, Qu, & Dallas, 2017). Only peptides 149 
with 100% homology to known functional peptides were considered as bioactive peptides. 150 
The relative amount of the bioactive peptides was estimated by integrating the area under the peak 151 
(AUP). AUP was measured from the extracted ion chromatograms (EIC) obtained for each peptide 152 
and normalized to the peptide content of milk hydrolysates. The peptide content was determined at 153 
the end of the fermentation trials by using the TNBS method as described in section 2.4 and 154 
expressing the results as mg of leucine equivalent mL-1 155 
. 156 
2.7 Calculation of the cleavage specificity 157 
The cleavage probability and positive or negative influence on the cleavage of an amino acid 158 
in the P1 and P1’ subsites were calculated according to Keyl (1992). 159 
The subsite nomenclature was according to Schechter & Berger (1967) where the amino 160 
acid residues are designated as P1 in the N-terminal direction (on left of the sequence) and Pl’ in the 161 
C-terminal direction (on right of the sequence) from the cleaved bond. The subsite P1 interacts with 162 
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the subsite S1 in the enzyme active site, whereas the subsite P1’ interact with the subsite S1’ in the 163 
enzyme active site. Therefore, the peptidic bond cleaved by the protease was defined as the P1-P1’ 164 
bond. We quantitatively analysed the influence of specific amino acid residues in position P1 or 165 
P1’on the CEP cleavage probability. 166 
If the amino acid residue A is in the position n (P1 or P1’ subsite), the cleavage probability 167 
of the P1–P1’ bond will be: 168 
 169 
% =  
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  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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  170 
and in consequence the mean cleavage probability: 171 
% =   %20

#
 174 
 173 
The coefficient Kn was used to quantify the positive or negative influence of an amino acid 175 
residue A in the P1 and P1’ subsites: 176 
 = %% − 1 177 
Kn values >0 indicated a positive influence of the amino acid A in the specific subsite on the 178 
cleavage of the P1-P1’ bond, whereas Kn values <0 suggested a negative effect on the cleavage. 179 
2.8 Statistical analysis 180 
All data are presented as mean ± standard deviation (SD) for three replicates. The Student’s 181 
t-test was performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA). The 182 
differences were considered significant with P <0.05. Venn diagrams were drawn using the online 183 
tool VENNY 2.1.0 (Oliveros, 2015). 184 
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3. Results and Discussion 185 
3.1 Characterization of fermented milk 186 
Analysis of CEP activities on purified caseins could tend to overestimate the true 187 
caseinolytic capability of whole cells towards casein micelles in milk (Sadat-Mekmen et al., 2011b). 188 
The use of purified CEPs instead whole-cell anchored CEPs may also modify the specificity of the 189 
proteinase towards caseins (Fernández de Palencia et al., 1997). Therefore, we decided to evaluate 190 
the CEP activities of whole cells of Lb. casei PRA205 and Lb. rhamnosus PRA331 towards the 191 
caseins in UHT milk.  192 
Milk samples were inoculated with standardized amounts of PRA205 and PRA331 single 193 
cultures without any pre-adaptation step. After 72h of incubation, pH values were 4.00 in both sets 194 
of samples and remained stable over time. At the end of fermentation, strain PRA205 showed value 195 
of leucine equivalents of 10.93 ± 0.93 mmol L-1, whereas PRA331 of 6.40 ± 0.92 mmol L-1. These 196 
data agree with earlier results showing that PRA205 is more proteolytic than PRA331 towards milk 197 
caseins (Solieri et al., 2015). Lb. casei PRA205 produced milk hydrolysates with ACEi activity 198 
higher than that exhibited by milk hydrolysates with Lb. rhamnosus PRA331 (75.8 ± 3.2 vs 68.5 ± 199 
2.6 ACEi%). Similarly, antioxidant activity was slightly higher in hydrolysates by strain PRA205 200 
than the hydrolysates by strain PRA331 (249.12 ± 15.10 vs 202.57 ± 18.66 mg L-1 of trolox, 201 
respectively). 202 
The level of bacterial lysis during milk fermentation was monitored to exclude that the 203 
peptides could be generated by intracellular peptidases released into the hydrolysates. Cell viability 204 
was estimated app. 100% for both PRA205 and PRA331 after 24 and 48h of incubation (data not 205 
showed). Interestingly, at the end of milk fermentation the percentage of viable cells was 90.49 ± 206 
0.74% and 94.59 ± 5.70% for PRA205 and PRA331, respectively. These data indicated that no 207 
significant lysis occurred during milk fermentation and supported that the observed casein 208 
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proteolysis was mainly due to the action of CEPs anchored on the whole cells rather than 209 
intracellular proteinases or peptidases. 210 
3.2. Peptidomic analysis of milk fermented with Lactobacillus casei PRA205 and Lactobacillus 211 
rhamnosus PRA331 212 
Mass spectrometry analysis was used to identify the full set of peptides present in milk 213 
hydrolysates by the selected strains. A total of 331 milk peptides were released by the CEPs 214 
activities of PRA205 and PRA331 whole cells. In particular, 178 peptides were identified in 215 
PRA205 samples (see supplementary online Tables S1-S4 and Figures S1-S4) and 153 peptides in 216 
PRA331 samples (see supplementary online Tables S5-S8 and Figures S1-S4).  217 
The analysis of the identified sequences according to their protein of origin showed that the 218 
main identified peptides were derived from β-casein, which was the preferred substrate over αS1-, 219 
κ- and αS2-caseins. The β-casein-derived peptides were 59.0 and 60.1% of the total identified 220 
peptides in PRA205 and PRA331 samples, respectively, followed by αS1-casein-derived peptides 221 
(18.5 and 19.0% of the total identified peptides in PRA205 and PRA331 samples, respectively) and 222 
κ-casein-derived peptides (16.3 and 15.0% of the total identified peptides in PRA205 and PRA331 223 
samples, respectively). PRA205 and PRA331 CEPs poorly hydrolysed αS2-casein, resulting in only 224 
11 (corresponding to the 6.2% of total identified peptides) and 8 peptides (corresponding to the 225 
5.9% of total identified peptides), respectively. As expected, no significant proteolysis of whey 226 
proteins was observed for both the strains. The Venn diagram (Figure 1) showed that 24.6 and 227 
14.0% of peptides were specific for PRA205 and PRA331 milk hydrolysates, respectively. The 228 
majority of the identified peptides were found in both the milk hydrolysates, suggesting that 229 
PRA205 and PRA331 share a similar caseinolytic pattern. 230 
CEPs are classified on the basis on their caseinolytic specificity (Kunji et al. 1996). 231 
Typically, two CEPs have been identified: a PI-type, which preferentially hydrolyses β-casein, and a 232 
PIII-type, which acts on αS1-, β- and κ –caseins equally well (Pritchard & Coolbear, 1993; Visser, 233 
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Exterkate, Slangen & de Veer 1986). A third group, termed PI/PIII-type has been described to 234 
classify intermediate proteases, capable to cleave β-casein like the PI-type and, to a lesser extent, α- 235 
and κ-caseins (Exterkate, Alting, & Bruinenberg, 1993). Both Lb. casei PRA205 and Lb. rhamnosus 236 
PRA331 exhibited a predominant CEP activity towards β-casein, and a lower proteolytic activity 237 
towards α- and κ-caseins. Cell viability data allowed us to exclude that intracellular aminopeptidase 238 
released by lysed cells may significantly contribute to this pattern of casein breakdown. 239 
Furthermore, no extracellular aminopeptidases have been reported for Lb. casei and Lb. rhamnosus 240 
(Christensen, Dudley, Pederson, & Steele, 1999). Overall, these evidences support that the observed 241 
CEP activities could be due to the mixed PI/PIII-type proteases. PI/PIII-type proteases have been 242 
characterized in lactobacilli (Fernandez de Palencia et al., 1997; Sadat-Mekmene et al., 2011a 243 
Villegas et al., 2015) and lactococci (Nikolić, Tolinački, Fira, Golić, & Topisirović, 2009). In 244 
particular, like PRA331, Lb. rhamnosus BGT10 has PrtR protease suitable to cleave both β- and α-245 
caseins.  246 
3.3. Analysis of the αS1-casein (f1-23) cleavage sites 247 
CEPs are commonly classified according to their specificities toward the αS1-casein fragment 248 
comprising residues from 1 to 23 (Exterkate, 1995). In strains PRA205 and PRA331, CEPs 249 
hydrolysed the αS1-casein (f1-23) fragment at the H8-Q9, Q9-G10, Q13-E14, N17-E18 and L21-R22 250 
positions, respectively
 
(Figure 2). In addition, PRA331 also cleaved at the L16-N17 position. The 251 
majority of these cleavage sites are typical of mixed PI/PIII-type CEPs isolated from several 252 
lactococci, S. thermophilus CNRZ 385, Lb. delbrueckii subsp. lactis CRL 581 and Lb. helveticus 253 
L89 (Exterkate, 1995; Fernandez-Espla, Garault, Monnet, & Rul, 2000; Hebert et al., 2008; Kunji et 254 
al., 1996). Two additional cleavage sites were found at the P2-K3 and E18-N19 positions. The 255 
cleavage site E18-N19 has been already reported for the CEP of Lb. delbrueckii subsp. lactis CRL 256 
581 (Hebert et al., 2008), whereas the cleavage site P2-K3 has never been identified in any CEPs 257 
previously described from lactobacilli. These results collectively suggested that CEPs from Lb. 258 
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casei PRA205 and Lb. rhamnosus PRA331 could belong to the mixed PI/PIII-type. This result 259 
disagrees with the PI-type CEP previously characterized in Lb. casei HN14 (Kojic et al., 1991), 260 
while it is consistent with the mixed PI/PIII type CEPs isolated from Lb. rhamnosus CGMCC11055 261 
and Lb. casei subsp. casei IFLP 731 (Guo et al., 2016; Fernández de Palencia et al., 1997). Overall, 262 
these evidences strongly support the high level of intra- and inter-species variability in protease 263 
repertoire exhibited by lactobacilli (Liu, Bayjanov, Renckens, Nauta, & Siezen, 2010). As reported 264 
above, the cell viability near to 100% measured at the end of the fermentation trials allowed us to 265 
exclude that intracellular peptidase released from lysed cells may contribute to the hydrolysis of the 266 
fragment αS1-casein (f1-23). Indeed, as reported by Christensen, Broadbent, & Steele (2003), the 267 
presence of cytoplasmic peptidase should results in an almost complete breakdown of the peptide 268 
αS1-casein (f1-9). 269 
 270 
3.4. Analysis of the β-casein cleavage site-specificity 271 
The cleavage site-specificity of PRA205 and PRA331 CEPs was determined using β-casein 272 
as preferred substrate (Figure 3). In total, 76 and 72 different cleavage sites were detected in 273 
samples hydrolysed by PRA205 and PRA331 whole cells, respectively. They constitute 36.5 and 274 
34.6% of all peptide bonds present in β-casein, showing that Lb. casei PRA205 and Lb. rhamnosus 275 
PRA331 CEPs have a very broad substrate specificity. These CEPs have almost the same 276 
specificity, as they shared 65% of cleavage sites. 277 
Amino acid sequence analysis of the identified peptides revealed that the cleavage sites were 278 
not concentrated at the N- or C-terminus, but rather distributed throughout the entire β-casein 279 
sequence for both the CEPs activities (Figure 3). Most of the proteinases previously described in 280 
lactobacilli have been proven to preferentially hydrolyse the C-terminal of β-casein (Lozo et al., 281 
2011). Recently, the PrtP proteinase isolated from Lb. rhamnosus CGMCC11055 breakdowns sites 282 
distributed along the whole β-casein sequence, like PRA205 and PRA331 CEPs (Guo et al., 2016). 283 
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Furthermore, we calculated the cleavage probability (%Pn) of the Lb. casei PRA205 CEP at 284 
the P1 and P1' positions (Table 1). This CEP cleaved preferentially when the P1 position was 285 
occupied by the hydrophobic amino acids M, L and F or the negatively charged amino acids Q and 286 
N primarily, and by the polar un-charged amino acid E to a lesser extent. Table 1 also shows how 287 
the amino acids at the P1’ position affected cleavage occurrence. PRA205 CEP exhibited cleavage 288 
preference towards the residues S, N, A and H in this position, whereas had a reduced preference 289 
for M, D, R and Y. Coefficients Kn were calculated to quantify the influence of different amino acid 290 
residues on the P1-P1’cleavage probabilities (Figure 4). Amino acids N, M, Q, F and L in the P1 291 
position and amino acids S, N, A and H in the P1’ position exerted the strongest positive effects on 292 
cleavage occurrence. The amino acids E in P1 position and V, M, D, R and Y in P1’ position also 293 
exerted a positive but weaker effect on cleavage probability. By contrast, G, I, P and D in the P1 294 
position and P and I in the P1’ position strongly inhibited the cleavage probability. Similarly, a 295 
negative effect was also found for the amino acids E and T at the P1’ position. Previous works 296 
found that CEPs preferentially cleave negatively charged and hydrophobic amino acids (Hebert et 297 
al., 2008; Juillard et al., 1995; Lozo et al., 2011; Monnet, Ley, & Gonzalez, 1992). For instance, Q 298 
and E at the P1 position positively affect the cleavage by CEP from Lb. delbrueckii subsp. lactis 299 
CRL 581 (Hebert et al., 2008), whereas the occurrence of Q and F at the same position positively 300 
affects the cleavage by CEPs from Lb. rhamnosus BGT10, Lb. helveticus BGRA43 and Lb. 301 
paracasei subsp. paracasei BGHN14 (Lozo et al., 2011). In Lb. casei PRA205 CEP exhibited a 302 
pattern of cleavage site preferences similar to PI/PIII-type CEP described in Lc. lactis subsp. lactis 303 
strain NCDO763 (Monnet, Ley, & Gonzalez, 1992), but different from those described for the PI-304 
type CEP in Lc. lactis subsp. cremoris strain Wg2 and for the PI/PIII-type CEP in Lb. rhamnosus 305 
strain CGMCC11055. In strain Wg2 the residue Y at the P1 position and the residues N and T at the 306 
P1’ position were preferred (Juillard et al., 1995), whereas in strain CGMCC11055 the residue P 307 
was preferred in both P1 and P1’ subsites (Guo et al., 2016). By contrast, strain NCDO763 had a 308 
CEP activity positively affected by Q and N at the P1 position, and by S and A at the P1’ position 309 
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(Monnet et al., 1992). Additionally, the residue P in both the P1 and P1’ positons negatively 310 
affected CEP cleavage in NCDO763 (Monnet et al., 1992). Similarly, the presence of a P residue 311 
bound to one of the preferred cleaved amino acids prevented CEP from Lb. casei PRA205 to cut the 312 
peptidic bond. For example, the preferentially cleaved amino acids Q and L formed seven and nine 313 
peptidic bonds with the amino acid P, respectively, but no one of these bonds was cleaved by 314 
PRA205 CEP (Figure 3). Finally, PRA205 CEP activity displayed the following two unique 315 
properties: M at the P1 position exerted a strong positive effect on cleavage occurrence, whereas I 316 
in both the P1 and P1’ positions exerted a strong negative effect. To the best of our knowledge, this 317 
cleavage site-specificity pattern has never been described in lactobacilli. 318 
As reported in Table 1 and Figure 4, CEP from Lb. rhamnosus PRA331 had a profile of 319 
cleavage specificity similar to Lb. casei PRA205. The main differences were the negative effect 320 
exerted by the amino acid H at the P1 position and the lack of the positive effect exerted by A at the 321 
P1’ position. 322 
3.5. Identification of bioactive peptides using functional peptides databases 323 
The peptides cleaved by PRA205 and PRA331 CEPs in milk hydrolysates were searched against 324 
the general bioactive peptide database BIOPEP (Minkiewicz et al., 2008) and the milk bioactive 325 
peptide database MBPDB (Nielsen et al., 2017), in order to find peptides which match sequences to 326 
known bioactive peptides. Out of 331 identified peptides, 24 shared 100% homologies with 327 
functional peptides previously reported to have various bioactivities (Table 2). These bioactive 328 
peptides represented 13.5% and 13.7% of the peptides totally released by Lb. casei PRA205 and Lb. 329 
rhamnosus PRA331 whole cells, respectively. Twenty-one peptides were commonly released by 330 
both the strains, whereas three peptides were uniquely identified in samples hydrolysed by Lb. casei 331 
PRA205 (Figure 1). Nineteen bioactive peptides derived from β-casein, four from αS1-casein and 332 
one from αS2-casein, whereas no bioactive peptides were found from κ-casein. (Table 2). The three 333 
Lb. casei PRA205-specific bioactive peptides were the β-casein fragments 192-209 334 
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(LYQEPVLGPVRGPFPIIV), 58-72 (LVYPFPGPIPNSLPQ) and 8-14 (VPGEIVE). Eighteen 335 
peptides were ACE-inhibitors, two had immunomodulatory activity, one showed dipeptidyl-336 
peptidase IV (DPPIV) inhibitory activity and one was an antimicrobial peptide. Two peptides, 337 
VYPFPGPIPN and YPFPGPIPN, were multi-functional bioactive peptides with ACEi, antioxidant 338 
and opioid agonist or ACEi, DPPIV-inhibitory and opioid agonist activities, respectively (Table 2). 339 
Among the peptides with ACEi activity, YPFPGPIPN, KVLPVPQ, RPKHPIKHQ and LHLPLP 340 
showed in vivo antihypertensive activity in spontaneously hypertensive rat (Maeno, Yamamoto, & 341 
Takano, 1996; Quirós et al., 2007; Saito, Nakamura, Kitazawa, Kawai, & Itoh, 2000). For all the 342 
other identified bioactive peptides, the bioactivity was previously demonstrated with in vitro assays. 343 
The physiological effects of bioactive peptides depend on their capability to arrive at the 344 
target organs in an active form (Udenigwe, & Fogliano, 2017). This required resistance to 345 
gastrointestinal proteases and brush border membrane peptidases, and absorption through the 346 
intestinal epithelium. Usually, P-containing peptides are considered resistant to degradation by 347 
digestive proteases. Peptides containing from one to four P residues in their sequences and with, in 348 
many cases, P at or near to carboxylic end, were found to survive in vitro gastro-intestinal digestion 349 
(Tagliazucchi et al., 2016). Among the identified bioactive peptides, seven of them were able to 350 
survive in vitro gastro-intestinal digestion (Picariello et al., 2015; Tagliazucchi et al., 2016) and 351 
were also found in human gastro-intestinal tract (Boutrou et al., 2013), namely DKIHPF, 352 
VYPFPGPIPN, YPFPGPIPN, NIPPLTQTPV, LHLPLP, FVAPFPEVF and VAPFPEVF. The 353 
intestinal brush-border membrane and the colonic cells also contain aminopeptidases e specific 354 
prolyl peptidases. However, the great quantity of P-rich peptides and the presence of peptides with 355 
inhibitory activities (as for example against DPP-IV and intestinal ACE) may slow down the action 356 
of prolyl peptidases, protecting the short peptides from hydrolysis and favouring their biological 357 
actions. Short peptides (two or three amino acids) are absorbed intact across the brush border 358 
membrane by a specific peptide transport system, whereas largest peptides via paracellular and/or 359 
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transcellular mechanisms (Vermeirssen, Van Camp, & Verstraete, 2004). The peptide LHLPLP 360 
showed in vivo anti-hypertensive activity in rats, and, after incubation with Caco-2 cells, it was 361 
hydrolysed by cellular peptidases to HLPLP prior to transport across the intestinal epithelium 362 
(Quirós, Dávalos, Lasunción, Ramos, & Recio, 2008). The penta-peptide HLPLP showed an 363 
absolute bioavailability of 5.2% and an absorption half-life of 2.8 min in rats (Sánchez-Rivera et al., 364 
2014). HLPLP was found to be hydrolysed by plasma peptidases in shorter peptides, which retained 365 
the anti-hypertensive properties in rats (Quirós et al., 2008; Sánchez-Rivera et al., 2014; Sánchez-366 
Rivera et al., 2016). No data on absorption or pharmacokinetics of the other identified bioactive 367 
peptides are available in literature. 368 
 369 
3.6. Bioactive peptides abundance across PRA205 and PRA331 fermented milk 370 
Each identified bioactive peptide was relatively quantified in the samples by integrating the 371 
area under the peak (AUP) from the extracted ion chromatogram. The ionization of specific 372 
peptides in mass spectrometry experiments is a major limitation in quantitative analysis with 373 
electrospray ionization mass spectrometry (ESI-MS). The relative ionization of individual peptides 374 
is dependent on intrinsic and extrinsic factors. The most important extrinsic factor is the so-called 375 
“matrix effect” which is caused by the co-elution of matrix components (typically salts, ions, highly 376 
polar compounds and carbohydrates) that alter, either suppressing or enhancing, the ionization of 377 
the target analyte (Furey, Moriarty, Bane, Kinsella, & Lehane 2013). The intrinsic factor are related 378 
to the amino acid sequence of the peptides. Some amino acids, such as basic or hydrophobic amino 379 
acids, are ionized more efficiently than the others and gave more intense signal in ESI-MS 380 
experiments (Cech, & Enke, 2000). Here, we compared the relative amount (expressed as AUP) of 381 
the same peptide in two different hydrolysates coming from the same matrix (fermented milk), thus 382 
we can exclude errors related to the extrinsic effect and assume that differences in peak intensity of 383 
the same analyte accurately reflects relative differences in its abundance.  384 
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Among the bioactive peptides detected in both milk hydrolysates, 17 exhibited mean 385 
abundances significantly different between Lb. casei PRA205 and Lb. rhamnosus PRA331 386 
(P<0.05). In particular, five peptides were more abundant in Lb. casei PRA205 milk hydrolysates 387 
and twelve in Lb. rhamnosus PRA331 milk hydrolysates (Table 2). When peptides intensities were 388 
summed, the bioactive peptides released by Lb. rhamnosus PRA331 whole cells were significantly 389 
higher than those released by Lb. casei PRA205 (11.50x1010 ± 0.39x1010 vs. 8.63x1010 ± 0.37x1010; 390 
P=0.0007). 391 
4. Conclusions 392 
Nowadays, there is an increasing interest in developing novel dairy healthy products. 393 
Studies on strains Lb. casei PRA205 and Lb. rhamnosus PRA331 may represent a proof-of-concept 394 
of the working flowchart to develop novel functional adjunct culture and the subsequent functional 395 
delivery food. We isolated proteolytic and stress-resistant strains from a stressful food niche (no 396 
sugars available, high salt concentration, low aw), such as Parmigiano Reggiano, and identified 397 
them using a rigorous polyphasic identification frame-shift (Solieri et al., 2012). We demonstrated 398 
that all of them are safe (sensitive to all tested antibiotics) and some resistant to in vitro gastro-399 
intestinal conditions (Solieri et al., 2014). We positively tested their ability to release VPP and IPP 400 
both in milk (Solieri et al., 2015) and in yogurt (Rutella et al., 2016), supporting the development of 401 
a double functional food, i.e. yogurt enriched in potentially probiotic viable cells and in 402 
antihypertensive peptides released by themselves. In this work, we characterized the CEPs that are 403 
the first enzymatic activities responsible for these relevant proteolytic features. For this purpose, a 404 
cutting-edge peptidomic approach was implemented in order to define the pattern of caseins 405 
breakdown by CEP activity from whole cells grown in milk. We demonstrated that CEPs activities 406 
of Lb. casei PRA205 and Lb. rhamnosus PRA331showed two unique features: a new cleavage site 407 
(P2-K3) on the αS1-casein fragment 1-23 and a novel pattern of β-casein cleavage site-specificity. 408 
Through a BIOPEP and MBPDB databases analysis, we also demonstrated that several identified 409 
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peptides matched the sequences of previously reported bioactive peptides. This information could 410 
be relevant, mainly considering the wide heterogeneity in distribution of different proteinase-411 
encoding genes among and within Lactobacillus species. Comparative genome analysis showed that 412 
lactobacilli strongly differ in the components of their proteolytic systems at strain level (Liu et al., 413 
2010). This strain-specificity accounts for the high phenotypic diversity in caseinolytic activity and 414 
in of the resulting released bioactive peptides, as well as makes necessary to deeply characterize 415 
each strain selected for functional food applications. However, it is important to note that protein 416 
hydrolysis catalysed by proteases is a dynamic process and that, in the present work, bioactive 417 
peptides were identified in fermented milk samples at one single time. We cannot exclude that 418 
shorter or longer incubation of milk with Lb. casei PRA205 and Lb. rhamnosus PRA331 whole 419 
cells may result in a different bioactive peptide profile of the samples. In addition, future 420 
biochemical assays with the synthesized peptides are needed to complement the in silico evidences 421 
collected here. 422 
Overall, the results provided in the present work will increase the knowledge about the 423 
proteolytic system of two important NS-LAB species, such as Lb. casei and Lb. rhamnosus, which 424 
are poorly studied compared to the best-described lactococci and thermophilic lactobacilli. Finally, 425 
since strains PRA205 and PRA331 released several potential bioactive peptides, they could be 426 
promising functional starters or adjunct cultures for formulating dairy products with health 427 
properties. 428 
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Figure Captions 
Figure 1. Venn diagram showing differences between Lactobacillus casei PRA205 and 
Lactobacillus rhamnosus PRA331 CEPs in patterns of peptides and bioactive peptides cleaved 
from milk caseins. The complete pattern of peptides identified at the end of the fermentation trials 
by mass spectrometry can be found in Supplementary on line Tables S1-S8. In the preparation of 
the Venn diagram related to bioactive peptides, only peptides found from the literature to have 
100% homology to known functional peptides were reported in the Figure. Peptides present in at 
least two of a triplicate’s samples were considered present. 
Figure 2. Specificity of CEPs from strains Lactobacillus casei PRA205 and Lactobacillus 
rhamnosus PRA331 toward αS1-casein fragment 1-23. The cleavage sites are indicated by 
arrows. 
Figure 3. Distribution of the cleavage sites identified in the primary sequences of β-casein by 
CEPs from Lactobacillus casei PRA205 and Lactobacillus rhamnosus PRA331. The cleavage 
sites are indicated by arrows. 
Figure 4. Cleavage preference of Lactobacillus casei PRA205 and Lactobacillus rhamnosus 
PRA331 CEPs towards eighteen amino acids at the P1 and P1’ subsites. (A) Influence of the 
different amino acids in the P1 subsite by CEP from Lb. casei PRA205. (B) Influence of the 
different amino acids in the P1’ subsite by CEP from Lb. casei PRA205. (C) Influence of the 
different amino acids in the P1 subsite by CEP from Lb. rhamnosus PRA331. (D) Influence of the 
different amino acids in the P1’ subsite by CEP from Lb. rhamnosus PRA331. See materials and 
methods section for the calculation of the coefficient Kn. Positive and negative values indicate a 
positive or negative influence exerted by each residue on the cleavage of the P1-P1’ bond, 
respectively. Please note that the amino acid C is not present in the sequence of β-casein, whereas 
W was omitted from the analysis since it occurs once in the β-casein sequence. 
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Table 3. Peptides with previously demonstrated bioactivity identified in the milk 
hydrolysates by whole cells of Lactobacillus casei PRA205 or Lactobacillus rhamnosus 
PRA331. 
Sequence Fragment Bioactivity PRA205 relative 
amounta (±SD) 
PRA331 relative 
amounta (±SD) P-value Reference 
   
   
 
LNVPGEIVE β-casein 
f(6-14) 
ACEi 1.13x109 ± 1.26x108 1.30x109 ± 4.21x107 0.0876 Gobbetti et 
al., 2000 
VPGEIVE β-casein 
f(8-14) 
DPPIV-inhibitor 4.30x108 ± 3.38x107 n.d. / Nongonierma 
et al., 2016 
DKIHPF β-casein 
f(47-52) 
ACEi 2.37x1010 ± 3.37x109 2.36x1010 ± 6.25x108 0.4925 Gobbetti et 
al., 2000 
LVYPFPGPIPNSLPQ β-casein 
f(58-72) 
ACE-inhibitor 3.44x108 ± 3.89x107 n.d. / Smacchi et 
al., 2008 
VYPFPGPIPN β-casein 
f(59-68) 
ACEi 
Antioxidant 
Opioid agonist 
8.19x109 ± 7.04x108 1.62x1010 ± 4.17x108 0.0004 Eisele et al., 
2013 
YPFPGPIPN β-casein 
f(60-68) 
ACEi 
DPPIV-inhibitor 
Opioid agonist 
3.34x109 ± 1.30x108 1.03x1010 ± 1.89x109 0.0030 Saito et al., 
2000 
NIPPLTQTPV β-casein 
f(73-82) 
ACEi 9.51x109 ± 5.72x108 5.96x109 ± 4.64x108 0.0027 
 
Gobbetti et 
al., 2000 
NLHLPLP β-casein 
f(132-138) 
ACEi 1.94x109 ± 2.09x108 7.81x108 ± 1.22x108 0.0031 Kohmura et 
al., 1989 
NLHLPLPLL β-casein 
f(132-140) 
ACEi 8.78x108 ± 3.33x107 5.92x108 ± 1.39x107 0.0037 Robert et al., 
2004 
LHLPLP β-casein 
f(133-138) 
ACEi 3.40x108 ± 3.47x107 7.64x108 ± 6.41x107 0.0072 Kohmura et 
al., 1989 
LHLPLPL β-casein 
f(133-139) 
ACEi 2.55x109 ± 2.85x108 3.06x109 ± 2.19x108 0.0920 Quiros et al., 
2007 
SQSKVLPVPQ β-casein 
f(166-175) 
ACEi 3.49x108 ± 3.51x107 6.14x108 ± 7.03x107 0.0050 Hayes et al., 
2007 
SKVLPVPQ β-casein 
f(168-175) 
ACEi 8.32x108 ± 1.07x108 1.07x109 ± 7.70x107 0.0380 Yamamoto et 
al., 1994 
KVLPVPQ β-casein 
f(169-175) 
ACEi 6.05x109 ± 5.74x108 1.40x1010 ± 1.76x109 0.0022 Maeno et al., 
1996 
RDMPIQAF β-casein 
f(183-190) 
ACEi 7.64x109 ± 2.57x108 1.33x109 ± 8.06x107 <0.0001 Yamamoto et 
al., 1994 
LYQEPVLGPVRGPFPIIV β-casein 
f(192-209) 
Immunomodulator 3.19x108 ± 4.13x107 n.d.  Boutrou et 
al., 2013 
YQEPVLGPVRGPFPIIV β-casein 
f(193-209) 
Immunomodulator  1.69x109 ± 3.86x108 1.21x109 ± 1.57x108 0.1237 Boutrou et 
al., 2013 
QEPVLGPVRGPFPIIV β-casein 
f(194-209) 
ACEi 7.53x109 ± 1.96x108 1.16x1010 ± 5.14x108 0.0044 Lu et al., 
2016 
EPVLGPVRGPFP β-casein 
f(195-206) 
ACEi 3.79x108 ± 3.38x107 4.90x108 ± 4.07x107 0.0219 Hayes et al., 
2007 
RPKHPIKHQ αS1-casein 
f(1-9) 
ACEi 7.10x109 ± 6.63x108 1.73x1010 ± 2.66x109 0.0032 Saito et al., 
2000 
ENLLRF αS1-casein 
f(18-24) 
ACEi 8.23x108 ± 1.76x108 1.46x109 ± 2.66x108 0.0226 Boutrou et 
al., 2013 
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FVAPFPEVF αS1-casein 
f(24-32) 
ACEi 7.27x108 ± 1.16x108 1.80x109 ± 6.93x107 0.0039 Boutrou et 
al., 2013 
VAPFPEVF αS1-casein 
f(25-32) 
ACEi 3.17x108 ± 3.39x107 1.48x109 ± 1.37x108 0.0003 Boutrou et 
al., 2013 
TKVIPYVRYL αS2-casein 
f(198-207) 
Antimicrobial 1.62x108 ± 3.75x107 5.30x107 ± 2.11x107 0.0180 Alvarez-
Ordóñez et 
al., 2013 
Abbreviations are: ACEi, angiotensin converting enzyme-inhibitory; DPPIV, dipeptidyl peptidase IV. 
aAmounts were calculated by measuring the area under the peak (AUP) from the extracted ion 
chromatograms (EIC) obtained for each peptide and AUP values were normalized to the total peptide 
content of the milk hydrolysates. Values are means ± standard deviation. Statistically significant 
differences between PRA205 and PRA331 samples were calculated by Student’s t-test (P<0.05). 
 




 Table 1. Cleavage occurrence and cleavage probability (%P) produced by Lactobacillus casei 
PRA205 and Lactobacillus rhamnosus PRA331 cell-envelope proteinase on β-casein at different 
amino acids in the P1 and P1’subsites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aOne code letter was used for amino acid nomenclature. The amino acid C is not present in the sequence of β-casein, 
while the amino acid W was omitted from the analysis since it occurs once in the β-casein sequence. 
bThe cleaved bonds are reported in Figure 3. 
cSee materials and methods section for the calculation of the %P1 and %P1’ cleavage probability. 
 Lb. casei PRA205 Lb. rhamnosus PRA331 
Amino acidsa 
Number 
of 
residues 
P1 subsite  P1’ subsite  Number 
of 
residues 
P1 subsite  P1’ subsite  
Number of 
cleaved bondb 
(%P1c) 
Number of 
cleaved bondb 
(%P1’c) 
Number of 
cleaved bondb 
(%P1c) 
Number of 
cleaved bondb 
(%P1’c) 
       
Aliphatic amino 
acids 
  
 
   
       
A 5 2 (40.0) 3 (60.0) 5 2 (40.0) 2 (40.0) 
G 5 0 (0) 2 (40.0) 5 0 (0) 2 (40.0) 
V 18 7 (38.9) 9 (50.0) 18 5 (27.8) 8 (44.4) 
L 22 12 (54.6) 10 (45.5) 22 12 (54.6) 10 (45.5) 
I 10 1 (10.0) 2 (20.0) 10 2 (20.0) 1 (10.0) 
M 6 4 (66.7) 3 (50.0) 6 4 (66.7) 3 (50.0) 
       
Polar un-charged 
amino acids 
  
 
  
 
       
T 9 3 (33.3) 2 (22.2) 9 3 (33.3) 2 (22.2) 
S 16 4 (25.0) 12 (75.0) 16 5 (31.3) 10 (61.5) 
E 19 9 (47.4) 3 (15.8) 19 8 (42.1) 3 (15.8) 
D 4 0 (0) 2 (50.0) 4 0 (0) 2 (50.0) 
P 35 5 (14.3) 2 (5.7) 35 6 (17.1) 2 (5.7) 
       
Positively 
charged amino 
acids 
  
 
  
 
       
R 4 1 (25.0) 2 (50.0) 4 1 (25.0) 2 (50.0) 
K 11 4 (36.4) 4 (36.4) 11 3 (27.3) 5 (45.5) 
H 5 2 (40.0) 3 (60.0) 5 1 (20.0) 3 (60.0) 
       
Negatively 
charged amino 
acids 
  
 
  
 
       
Q 20 11 (55.0) 8 (40.0) 20 10 (50.0) 9 (45.0) 
N 5 4 (80.0) 3 (60.0) 5 3 (60.0) 3 (60.0) 
       
Aromatic amino 
acids 
  
 
  
 
       
F 9 5 (55.6) 3 (33.3) 9 5 (55.7) 2 (22.2) 
Y 4 1 (25.0) 2 (50.0) 4 1 (25.0) 2 (50.0) 
 1 
 
 
Table 2. Peptides with previously demonstrated bioactivity identified in the milk 
hydrolysates by whole cells of Lactobacillus casei PRA205 or Lactobacillus rhamnosus 
PRA331. 
Sequence Fragment Bioactivity PRA205 relative 
amounta (±SD) 
PRA331 relative 
amounta (±SD) P-value Reference 
   
   
 
LNVPGEIVE β-casein 
f(6-14) 
ACEi 1.13x109 ± 1.26x108 1.30x109 ± 4.21x107 0.0876 Gobbetti et 
al., 2000 
VPGEIVE β-casein 
f(8-14) 
DPPIV-inhibitor 4.30x108 ± 3.38x107 n.d. / Nongonierma 
et al., 2016 
DKIHPF β-casein 
f(47-52) 
ACEi 2.37x1010 ± 3.37x109 2.36x1010 ± 6.25x108 0.4925 Gobbetti et 
al., 2000 
LVYPFPGPIPNSLPQ β-casein 
f(58-72) 
ACE-inhibitor 3.44x108 ± 3.89x107 n.d. / Smacchi et 
al., 2008 
VYPFPGPIPN β-casein 
f(59-68) 
ACEi 
Antioxidant 
Opioid agonist 
8.19x109 ± 7.04x108 1.62x1010 ± 4.17x108 0.0004 Eisele et al., 
2013 
YPFPGPIPN β-casein 
f(60-68) 
ACEi 
DPPIV-inhibitor 
Opioid agonist 
3.34x109 ± 1.30x108 1.03x1010 ± 1.89x109 0.0030 Saito et al., 
2000 
NIPPLTQTPV β-casein 
f(73-82) 
ACEi 9.51x109 ± 5.72x108 5.96x109 ± 4.64x108 0.0027 
 
Gobbetti et 
al., 2000 
NLHLPLP β-casein 
f(132-138) 
ACEi 1.94x109 ± 2.09x108 7.81x108 ± 1.22x108 0.0031 Kohmura et 
al., 1989 
NLHLPLPLL β-casein 
f(132-140) 
ACEi 8.78x108 ± 3.33x107 5.92x108 ± 1.39x107 0.0037 Robert et al., 
2004 
LHLPLP β-casein 
f(133-138) 
ACEi 3.40x108 ± 3.47x107 7.64x108 ± 6.41x107 0.0072 Kohmura et 
al., 1989 
LHLPLPL β-casein 
f(133-139) 
ACEi 2.55x109 ± 2.85x108 3.06x109 ± 2.19x108 0.0920 Quiros et al., 
2007 
SQSKVLPVPQ β-casein 
f(166-175) 
ACEi 3.49x108 ± 3.51x107 6.14x108 ± 7.03x107 0.0050 Hayes et al., 
2007 
SKVLPVPQ β-casein 
f(168-175) 
ACEi 8.32x108 ± 1.07x108 1.07x109 ± 7.70x107 0.0380 Yamamoto et 
al., 1994 
KVLPVPQ β-casein 
f(169-175) 
ACEi 6.05x109 ± 5.74x108 1.40x1010 ± 1.76x109 0.0022 Maeno et al., 
1996 
RDMPIQAF β-casein 
f(183-190) 
ACEi 7.64x109 ± 2.57x108 1.33x109 ± 8.06x107 <0.0001 Yamamoto et 
al., 1994 
LYQEPVLGPVRGPFPIIV β-casein 
f(192-209) 
Immunomodulator 3.19x108 ± 4.13x107 n.d.  Boutrou et 
al., 2013 
YQEPVLGPVRGPFPIIV β-casein 
f(193-209) 
Immunomodulator  1.69x109 ± 3.86x108 1.21x109 ± 1.57x108 0.1237 Boutrou et 
al., 2013 
QEPVLGPVRGPFPIIV β-casein 
f(194-209) 
ACEi 7.53x109 ± 1.96x108 1.16x1010 ± 5.14x108 0.0044 Lu et al., 
2016 
EPVLGPVRGPFP β-casein 
f(195-206) 
ACEi 3.79x108 ± 3.38x107 4.90x108 ± 4.07x107 0.0219 Hayes et al., 
2007 
RPKHPIKHQ αS1-casein 
f(1-9) 
ACEi 7.10x109 ± 6.63x108 1.73x1010 ± 2.66x109 0.0032 Saito et al., 
2000 
ENLLRF αS1-casein 
f(18-24) 
ACEi 8.23x108 ± 1.76x108 1.46x109 ± 2.66x108 0.0226 Boutrou et 
al., 2013 
 2 
 
FVAPFPEVF αS1-casein 
f(24-32) 
ACEi 7.27x108 ± 1.16x108 1.80x109 ± 6.93x107 0.0039 Boutrou et 
al., 2013 
VAPFPEVF αS1-casein 
f(25-32) 
ACEi 3.17x108 ± 3.39x107 1.48x109 ± 1.37x108 0.0003 Boutrou et 
al., 2013 
TKVIPYVRYL αS2-casein 
f(198-207) 
Antimicrobial 1.62x108 ± 3.75x107 5.30x107 ± 2.11x107 0.0180 Alvarez-
Ordóñez et 
al., 2013 
Abbreviations are: ACEi, angiotensin converting enzyme-inhibitory; DPPIV, dipeptidyl peptidase IV. Only 
peptides found from the literature to have 100% homology to known functional peptides were reported in 
the Table. The complete list of identified peptides can be found in Supplementary on line Tables S1-S8. 
aAmounts were calculated by measuring the area under the peak (AUP) from the extracted ion 
chromatograms (EIC) obtained for each peptide and AUP values were normalized to the total peptide 
content of the milk hydrolysates as described in section 2.6. Values are means ± standard deviation. 
Statistically significant differences between PRA205 and PRA331 samples were calculated by Student’s t-
test (P<0.05). 
 
Figure S1. β-casein derived peptides identified in the TCA-soluble supernatant obtained from milk 
fermented with Lactobacillus casei PRA205 and Lactobacillus rhamnosus PRA331. The peptides 
are reported as bars below the corresponding amino acid sequences. Red bars correspond to 
peptides with angiotensin-converting enzyme (ACE) inhibitory activity. Yellow bars correspond to 
peptides with dipeptidyl peptidase IV (DPP-IV) inhibitory activity. Green bars correspond to 
peptides with antioxidant activity. Light blue bars correspond to peptides with anti-microbial 
activity. Blue bars correspond to peptides with opioid agonist activity. Purple bars correspond to 
peptides with immunomodulation activity. Peptides with more than one activity are presented with 
multi-colour bars. 
Figure S2. αS1-casein derived peptides identified in the TCA-soluble supernatant obtained from 
milk fermented with Lactobacillus casei PRA205 and Lactobacillus rhamnosus PRA331. The 
peptides are reported as bars below the corresponding amino acid sequences. Red bars correspond 
to peptides with angiotensin-converting enzyme (ACE) inhibitory activity. Yellow bars correspond 
to peptides with dipeptidyl peptidase IV (DPP-IV) inhibitory activity. Green bars correspond to 
peptides with antioxidant activity. Light blue bars correspond to peptides with anti-microbial 
activity. Blue bars correspond to peptides with opioid agonist activity. Purple bars correspond to 
peptides with immunomodulation activity. Peptides with more than one activity are presented with 
multi-colour bars.  
Figure S3. αS2-casein derived peptides identified in the TCA-soluble supernatant obtained from 
milk fermented with Lactobacillus casei PRA205 and Lactobacillus rhamnosus PRA331. The 
peptides are reported as bars below the corresponding amino acid sequences. Red bars correspond 
to peptides with angiotensin-converting enzyme (ACE) inhibitory activity. Yellow bars correspond 
to peptides with dipeptidyl peptidase IV (DPP-IV) inhibitory activity. Green bars correspond to 
peptides with antioxidant activity. Light blue bars correspond to peptides with anti-microbial 
activity. Blue bars correspond to peptides with opioid agonist activity. Purple bars correspond to 
peptides with immunomodulation activity. Peptides with more than one activity are presented with 
multi-colour bars. 
Figure S4. κ-casein derived peptides identified in the TCA-soluble supernatant obtained from milk 
fermented with Lactobacillus casei PRA205 and Lactobacillus rhamnosus PRA331. The peptides 
are reported as bars below the corresponding amino acid sequences. Red bars correspond to 
peptides with angiotensin-converting enzyme (ACE) inhibitory activity. Yellow bars correspond to 
peptides with dipeptidyl peptidase IV (DPP-IV) inhibitory activity. Green bars correspond to 
peptides with antioxidant activity. Light blue bars correspond to peptides with anti-microbial 
activity. Blue bars correspond to peptides with opioid agonist activity. Purple bars correspond to 
peptides with immunomodulation activity. Peptides with more than one activity are presented with 
multi-colour bars. 
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Table S1. β-casein-derived peptides identified in milk fermented with Lactobacillus 
casei PRA205 whole cellsa. 
Sequenceb Observed 
mass (m/z)c 
Calculated 
massd 
Fragment Bioactivitye Reference 
  
 
   
LNVPGEIVE 969.5562 968.5179 f(6-14) ACEi Gobbetti et al., 
2000 
NVPGEIVE 856.4430 855.4338 f(7-14) / / 
VPGEIVE 742.3943 
 
741.3909 f(8-14) DPPIV-inhibitor Nongonierma 
et al., 2016 
SITRIN 352.1970 702.4024 f(22-27) / / 
KKIEKF 396.7429 791.4905 f(28-33) / / 
KKIEKFQ 460.7709 919.5491 f(28-34) / / 
KKIEKFQS(phospho)E 608.8120 1215.5900 f(28-36) / / 
KKIEKFQS(phospho)EE 673.3181 1344.6326 f(28-37) / / 
IEKFQS(phospho)EE 545.2067 1088.4427 
 
f(30-37) / / 
DKIHPF 756.3786 755.3966 f(47-52) ACEi Gobbetti et al., 
2000 
DKIHPFAQTQ 592.7785 1183.5986 f(47-56) / / 
SLVYPFPGPIPN 650.8484 1299.6863 f(57-68) / / 
SLVYPFPGPIPNSLPQ 863.4501 1724.9138 f(57-72) / / 
LVYPFPGPIPN 1213.6762 1212.6543 f(58-68) / / 
LVYPFPGPIPNSLPQ 819.9604 1724.9138 f(58-72) ACEi Smacchi et al., 
2008 
VYPFPGPIPN 1100.5568 1099.5702 f(59-68) ACEi 
Antioxidant 
Opioid agonist 
Eisele et al., 
2013 
VYPFPGPIPNSLPQ 763.4073 1524.7977 f(59-72) / / 
YPFPGPIPN 1001.5291 1000.5018 f(60-68) ACEi 
DPPIV-inhibitor 
Opioid agonist 
Saito et al., 
2000 
SLPQNIPPL 978.5771 977.5546 f(69-77) / / 
SLPQNIPPLTQTPVVVPPFLQPEVM(ox) 919.8153 2755.4823 f(69-93) / / 
NIPPLTQTPV 1079.6176 1078.6023 f(73-82) ACEi Gobbetti et al., 
2000 
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NIPPLTQTPVVVPPF 809.9563 1617.9131 f(73-87) / / 
NIPPLTQTPVVVPPFLQPEVM 772.7640 2315.2599 f(73-93) / / 
TQTPV 545.2884 544.2857 f(78-82) / / 
TQTPVVVPPF 1084.5754 1083.5965 f(78-87) / / 
TQTPVVVPPFLQPE 776.4502 1550.8345 f(78-91) / / 
TQTPVVVPPFLQPEVM 891.4896 1780.9434 f(78-93) / / 
TQTPVVVPPFLQPEVMGV 969.5306 1937.0333 f(78-95) / / 
TQTPVVVPPFLQPEVMGVSKVKEAMAP 960.5079 2878.5337 f(78-104) / / 
QTPVVVPPFLQPEVM 840.9568 1679.8957 f(79-93) / / 
PVVVPPFLQPEVM 726.4071 1450.7894 f(81-93) / / 
VVPPFLQPE 1025.6040 1024.5593 f(83-91) / / 
VVPPFLQPEVM 1255.6987 1254.6682 f(83-93) / / 
VPPFLQPE 463.7369 925.4909 f(84-91) / / 
VPPFLQPEVM 578.7970 1155.5968 f(84-93) / / 
PPFLQPE 827.4361 826.4225 f(85-91) / / 
LQPEVM 716.3580 715.3575 f(88-93) / / 
AMAPKHKEMPFPKYPVEPF 748.7340 2243.1271 f(101-119) / / 
MAPKHKEMPFPKYPVEPF 725.0321 2172.0900 f(102-119) / / 
APKHKEMPFPKYPVEPF 681.3579 2041.0495 f(103-119) / / 
APKHKEMPFPKYPVEPFTESQ 622.5635 2486.2304 f(103-123) / / 
KHKEMPFPKYPVEPF 625.3218 1872.9596 f(105-119) / / 
HKEMPFPKYPVEPF 582.6372 1744.8647 f(106-119) / / 
HKEMPFPKYPVEPFTESQ 730.9973 2190.0456 f(106-123) / / 
EMPFPKYPVEP 667.3054 1332.6424 f(108-118) / / 
EMPFPKYPVEPF 740.8620 1479.7108 f(108-119) / / 
MPFPKYPVEP 602.8135 1203.5998 f(109-118) / / 
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MPFPKYPVEPF 676.3415 1350.6682 f(109-119) / / 
NLHLPLP 402.2601 801.4701 f(132-138) ACEi Kohmura et 
al., 1989 
NLHLPLPL 916.5616 915.5542 f(132-139) / / 
NLHLPLPLL 515.3168 1028.6382 f(132-140) ACEi Robert et al., 
2004 
NLHLPLPLLQ 579.3496 1156.6968 f(132-141) / / 
NLHLPLPLLQS 622.8851 1243.7288 f(132-142) / / 
NLHLPLPLLQSW 715.9295 1429.8082 f(132-143) / / 
LHLPLP 345.2209 688.4272 f(133-138) ACEi Kohmura et 
al., 1989 
LHLPLPL 401.7546 801.5112 f(133-139) ACEi Quiros et al., 
2007 
LHLPLPLLQ 1043.6493 1042.6539 f(133-141) / / 
LHLPLPLLQS 565.8369 1129.6859 f(133-142) / / 
LHLPLPLLQSW 658.9507 1315.7652 f(133-143) / / 
HLPLPLLQ 465.7873 929.5698 f(134-141) / / 
HLPLPLLQSW 602.3328 1202.6812 f(134-143) / / 
LPLPLLQ 793.5148 792.5109 f(135-141) / / 
LPLPLLQSW 1066.6182 1065.6223 f(135-143) / / 
WMHQPHQPLPPT 490.2347 1467.7081 f(143-154) / / 
WMHQPHQPLPPTVM 566.9374 1697.8170 f(143-156) / / 
MHQPHQPLPPT 641.8116 1281.6288 f(144-154) / / 
MHQPHQPLPPTVM 756.8776 1511.7377 f(144-156) / / 
MHQPHQPLPPTVMFPPQ 661.3254 1982.3793 f(144-160) / / 
HQPHQPLPPT 576.2953 1150.5883 f(145-154) / / 
HQPHQPLPPTVM 691.3551 1370.6972 f(145-156) / / 
HQPHQPLPPTVMFPPQ 617.6508 1849.9298 f(145-160) / / 
QPHQPLPPTVM 622.8084 1243.6383 f(146-156) / / 
VMFPPQ 359.6717 717.3520 f(155-160) / / 
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VMFPPQSVL 1017.5629 1016.5365 f(155-163) / / 
FPPQSVL 787.4301 786.4276 f(157-163) / / 
SQSKVLPVPQ 541.8009 1071.6132 f(166-175) ACEi Hayes et al., 
2007 
QSKVLPVPQ 995.5916 994.5811 f(167-175) / / 
QSKVLPVPQKAVPYPQR 484.5272 1934.1102 f(167-182) / / 
SKVLPVPQ 434.2542 866.5226 f(168-175) ACEi Yamamoto et 
al., 1994 
KVLPVPQ 390.7414 779.4905 f(169-175) ACEi Maeno et al., 
1996 
VLPVPQ 652.3973 651.3956 f(170-175) / / 
KAVPYPQ 401.7171 801.4385 f(176-182) / / 
KAVPYPQR 479.7656 957.5396 f(176-183) / / 
RDMPIQA 415.7139 829.4116 f(183-189) / / 
RDMPIQAF 489.2411 976.4800 f(183-190) ACEi Yamamoto et 
al., 1994 
RDMPIQAFLL 602.3328 1202.6481 f(183-192) / / 
LYQEPVL 861.4568 860.4644 f(192-198) / / 
LYQEPVLGPVRGPFP 834.9509 1667.9035 f(192-206) / / 
LYQEPVLGPVRGPFPIIV 997.5960 1993.1401 f(192-209) Immunomodulator Boutrou et al., 
2013 
YQEPVL 748.3554 747.3803 f(193-198) / / 
YQEPVLGPVRGPFP 778.4137 1554.8195 f(193-206) / / 
YQEPVLGPVRGPFPIIV 941.0462 1880.0560 f(193-209) Immunomodulator Boutrou et al., 
2013 
QEPVL 585.3251 584.3170 f(194-198) / / 
QEPVLGPVRGPFP 696.8883 1391.7561 f(194-206) / / 
QEPVLGPVRGPFPII 809.9563 1617.9243 f(194-208) / / 
QEPVLGPVRGPFPIIV 859.4987 1716.9927 f(194-209) ACEi Lu et al., 2016 
EPVLGPVRGPFP 632.8584 1263.6976 f(195-206) ACEi Hayes et al., 
2007 
EPVLGPVRGPFPIIV 795.4756 1588.9341 f(195-209) / / 
VLGPVRGPFPIIV 682.4140 1362.8388 f(197-209) / / 
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LGPVRGPFPIIV 632.8902 1263.7703 f(198-209) / / 
GPVRGPFP 413.7223 825.4497 f(199-206) / / 
GPVRGPFPII 526.8104 1051.6179 f(199-208) / / 
GPVRGPFPIIV 576.3457 1150.6863 f(199-209) / / 
RGPFPIIV 449.7709 897.5436 f(202-209) / / 
aAbbreviations are: ACEi, angiotensin converting enzyme-inhibitory; DPPIV, dipeptidyl peptidase IV. 
bOne code letter was used for amino acid nomenclature. 
cThe observed mass is reported as [M+nH]n+. 
dThe calculated mass is in Da. 
ePotential bioactivities were retrieved by searching peptide sequences against the BIOPEP and MBPDB 
databases (Minkiewicz et al., 2008; Nielsen et al., 2017). 
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Table S2. αS1-casein-derived peptides identified in milk fermented with Lactobacillus 
casei PRA205 whole cellsa. 
Sequenceb Observed 
mass (m/z)c 
Calculated 
massd 
Fragment Bioactivitye Reference 
RPKHPIKH 338.2150 1011.6090 f(1-8) / / 
RPKHPIKHQ 570.8322 1139.6676 f(1-9) ACEi Saito et al., 
2000 
RPKHPIKHQGLPQ 512.6430 1534.8844 f(1-13) / / 
RPKHPIKHQGLPQEVLN 498.5285 1990.1224 f(1-17) / / 
KHPIKHQ 296.4995 886.5137 f(3-9) / / 
GLPQEVLNE 499.7432 997.5080 f(10-18) / / 
ENLLRF 396.2126 790.4337 f(18-24) ACEi Boutrou et 
al., 2013 
FVAPFPE 806.3771 805.4010 f(24-30) / / 
FVAPFPEVF 1052.5566 1051.5379 f(24-32) ACEi Boutrou et 
al., 2013 
FVAPFPEVFGKE 683.8712 1365.6969 f(24-35) / / 
VAPFPE 659.3117 658.3326 f(25-30) / / 
VAPFPEVF 453.2311 904.4695 f(25-32) ACEi Boutrou et 
al., 2013 
VAPFPEVFGK 545.7962 1089.5859 f(25-34) / / 
VAPFPEVFGKE 610.2613 1218.6285 f(25-35) / / 
VFGKEKV 403.7262 805.4698 f(31-37) / / 
VFGKEKVN 307.4989 919.5127 f(31-38) / / 
VFGKEKVNEL 581.8127 1161.6394 f(31-40) / / 
S(phospho)VEQKHIQ 524.7428 1047.4750 f(75-82) / / 
RLKKYKVPQ 387.2312 1158.7237 f(100-108) / / 
KKYKVPQ 445.7761 889.5385 f(102-108) / / 
KYKVPQ 381.7173 761.4436 f(103-108) / / 
LEIVPN 684.3778 683.3854 f(109-114) / / 
S(phospho)AEELRH 461.1781 920.3753 f(115-121) / / 
SMKEGIH 401.1859 800.3851 f(122-128) / / 
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KEGIHAQ 391.7040 781.4082 f(124-130) / / 
AQQKEPM 416.1894 830.3956 f(139-135) / / 
QKEPMIGVN 508.2554 1014.5168 f(131-139) / / 
FSDIPNPIGSE 1175.5582 1174.5506 f(179-189) / / 
FSDIPNPIGSEN 645.2999 1288.5935 f(179-190) / / 
FSDIPNPIGSENSE 753.3396 1504.6682 f(179-192) / / 
FSDIPNPIGSENSEK 817.3947 1632.7631 f(179-193) / / 
SDIPNPIGSENSE 679.7936 1357.5997 f(180-192) / / 
DIPNPIGSENSE 636.2773 1270.5677 f(181-192) / / 
aAbbreviation is: ACEi, angiotensin converting enzyme-inhibitory. 
bOne code letter was used for amino acid nomenclature. 
cThe observed mass is reported as [M+nH]n+. 
dThe calculated mass is in Da. 
ePotential bioactivities were retrieved by searching peptide sequences against the BIOPEP and MBPDB 
databases (Minkiewicz et al., 2008; Nielsen et al., 2017).  
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Table S3. αS2-casein-derived peptides identified in milk fermented with Lactobacillus 
casei PRA205 whole cells. 
Sequencea Observed 
mass (m/z)b 
Calculated 
massc 
Fragment Bioactivityd Reference 
SIIS(phospho)QETYK 574.7641 1147.5162 f(13-21) / / 
RNAVPITPT 484.7610 967.5451 f(114-122) / / 
NAVPITPT 812.4495 811.4440 f(115-122) / / 
NAVPITPTLNRE 662.8478 1323.7146 f(115-126) / / 
AVPITPT 698.4023 697.4010 f(116-122) / / 
AVPITPTLNRE 605.8537 1209.6717 f(116-126) / / 
LNREQLS(phospho)TS(phospho)EE 733.2800 1464.5534 f(123-133) / / 
NSKKTVD 396.2126 790.4185 f(134-140) / / 
MES(phospho)TEVFTK 576.2371 1150.4617 f(141-149) / / 
TKKTKLTE 474.7895 947.5651 f(148-155) / / 
TKVIPYVRYL 417.9110 1250.7387 f(198-207) Antimicrobial Alvarez-
Ordóñez et 
al., 2013 
aOne code letter was used for amino acid nomenclature. 
bThe observed mass is reported as [M+nH]n+. 
cThe calculated mass is in Da. 
dPotential bioactivities were retrieved by searching peptide sequences against the BIOPEP and MBPDB 
databases (Minkiewicz et al., 2008; Nielsen et al., 2017).  
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Table S4. κ-casein-derived peptides identified in milk fermented with Lactobacillus 
casei PRA205 whole cells. 
Sequencea Observed 
mass (m/z)b 
Calculated 
massc 
Fragment Bioactivityd Reference 
FSDKIA 340.6720 679.3541 f(18-23) / / 
KYIPIQY 462.7570 923.5116 f(24-30) / / 
KYIPIQYVL 568.8331 1135.6641 f(24-32) / / 
SRYPSYGLN 528.7613 1055.5036 f(33-41) / / 
YYQQKPV 463.2334 924.4705 f(42-48) / / 
YYQQKPVAL 555.2851 1108.5917 f(42-50) / / 
YYQQKPVALIN 668.8545 1335.7187 f(42-52) / / 
YYQQKPVALINN 725.8879 1449.7616 f(42-53) / / 
QKPVALINN 498.7884 995.5764 f(45-53) / / 
NQFLPYPYYAKPA 786.4022 1570.7820 f(53-65) / / 
QFLPYPYYAKPA 729.3616 1456.7391 f(54-65) / / 
FLPYPYYAKPA 665.3372 1328.7805 f(55-65) / / 
LPYPYYAKPA 591.8096 1181.6121 f(56-65) / / 
YAKPA 275.1487 548.2958 f(61-65) / / 
AVRSPA 300.6684 599.3391 f(66-71) / / 
AVRSPAQIL 477.7794 953.5658 f(66-74) / / 
AVRSPAQILQ 541.8009 1081.6244 f(66-75) / / 
ARHPHPHLS 351.1777 1050.5471 f(96-104) / / 
ARHPHPHLSF 400.2009 1197.6156 f(96-105) / / 
ARHPHPHLSFM 443.8951 1328.6560 f(96-106) / / 
DKTEIPTIN 515.7586 1029.5342 f(116-123) / / 
KTEIPTIN 458.2511 914.5073 f(117-123) / / 
EIPTIN 686.3773 685.3646 f(118-123) / / 
TIASGEPT 775.3848 774.3759 f(124-131) / / 
 10 
 
VATLEDS(phospho)PE 520.7034 1039.4111 f(143-152) / / 
VIESPPEIN 997.5065 996.5128 f(152-160) / / 
SPPEIN 656.3215 655.3177 f(155-160) / / 
SPPEINTVQ 984.5185 983.4924 f(155-163) / / 
VTSTAV 577.3151 576.3119 f(164-169) / / 
aOne code letter was used for amino acid nomenclature. 
bThe observed mass is reported as [M+nH]n+. 
cThe calculated mass is in Da.  
dPotential bioactivities were achieved retrieved by searching peptide sequences against the BIOPEP and 
MBPDB databases (Minkiewicz et al., 2008; Nielsen et al., 2017).  
 11 
 
References 
Alvarez-Ordóñez, A., Begley, M., Clifford, T., Deasy, T., Considine, K., & Hill, C. 
(2013). Structure-activity relationship of synthetic variants of the milk-derived 
antimicrobial peptide αs2-casein f(183-207). Applied and Environmental Microbiology, 
79, 5179-5185. 
Boutrou, R., Gaudichon, C., Dupont, D., Jardin, J., Airinei, G., Marsset-Baglieri, A., 
Benamouzig, R., Tomé, D., & Leonil, J. (2013). Sequential release of milk protein-
derived bioactive peptides in the jejunum in healthy humans. American Journal of 
Clinical Nutrition, 97, 1314-1323. 
Eisele, T., Stressler, T., Kranz, B., & Fischer, L. (2013). Bioactive peptides generated in 
an enzyme membrane reactor using Bacillus lentus alkaline peptidase. European Food 
Science and Technology, 236, 483-490. 
Gobbetti, M., Ferranti, P., Smacchi, E., Goffredi, F., & Addeo, F. (2000). Production of 
angiotensin-I-converting-enzyme-inhibitory peptides in fermented milks started by 
Lactobacillus delbrueckii subsp bulgaricus SS1 and Lactococcus lactis subsp cremoris 
FT4. Applied and Environmental Microbiology, 66, 3898–3904. 
Hayes, M., Stanton, C., Slattery, H., O’Sullivan, O., Hill, C., FitzGerald, G. F., & Ross, 
P. (2007). Casein fermentate of Lactobacillus animalis DPC6134 contains a range of 
novel propeptide angiotensin-converting enzyme inhibitors. Applied and 
Environmental Microbiology, 73, 4658–4667. 
Kohmura, M., Nio, N., Kubo, K., Minoshima, Y., Munekata, E., & Ariyoshi, Y. (1989). 
Inhibition of angiotensin-converting enzyme by synthetic peptides of human β-casein. 
Agricultural and Biological Chemistry, 53, 2107-2114. 
 12 
 
Lu, Y., Govindasamy-Lucey, S., & Lucey, J. A. (2016). Angiotensin-I-converting 
enzyme-inhibitory peptides in commercial Wisconsin Cheddar cheeses of different 
ages. Journal of Dairy Sciences, 99, 41-52. 
Maeno, M., Yamamoto, N., & Takano, T. (1996). Identification of an antihypertensive 
peptide from casein hydrolysate produced by a proteinase from Lactobacillus 
helveticus CP790. Journal of Dairy Science, 79, 1316-1321.  
Minkiewicz, P., Dziuba, J., Iwaniak, A., Dziuba, M., & Darewicz, M. (2008). BIOPEP 
database and other programs for processing bioactive peptide sequences. Journal of 
AOAC International, 91, 965-980. 
Nielsen, S. D., Beverly, R. L., Qu, Y., & Dallas, D. C. (2017). Milk bioactive peptide 
database: A comprehensive database of milk protein-derived bioactive peptides and 
novel visualization. Food Chemistry, 232, 673–82. 
Nongonierma, A. B., & FitzGerald, R. J. (2016). Structure activity relationship modelling 
of milk protein-derived peptides with dipeptidyl peptidase IV (DPP-IV) inhibitory 
activity. Peptides, 79, 1-7. 
Quirós, A., Ramos, M., Muguerza, B., Delgado, M. A., Miguel, M., Aleixandre, A., et al. 
(2007). Identification of novel antihypertensive peptides in milk fermented with 
Enterococcus faecalis. International Dairy Journal, 17, 33–41. 
Robert, M. C., Razaname, A., Mutter, M., & Juillerat, M. A. (2004). Identification of 
angiotensin-I-converting enzyme inhibitory peptides derived from sodium caseinate 
hydrolysates produced by Lactobacillus helveticus NCC 2765. Journal of Agricultural 
and Food Chemistry, 52, 6923-6931. 
 13 
 
Saito, T., Nakamura, T., Kitazawa, H., Kawai, Y., & Itoh, T. (2000). Isolation and 
structural analysis of antihypertensive peptides that exist naturally in gouda cheese. 
Journal of Dairy Science, 83, 1434-1440. 
Smacchi, E., & Gobbetti, M. (1998). Peptides from several italian cheeses inhibitory to 
proteolytic enzymes of lactic acid bacteria Pseudomonas fluorescens ATCC 948 and 
to the angiotensin I-converting enzyme. Enzyme and Microbial Technology, 22, 687-
694. 
Yamamoto, N., Akino, A., & Takano, T. (1994). Antihypertensive effect of the peptides 
derived from casein by an extracellular proteinase from Lactobacillus helveticus 
CP790. Journal of Dairy Science, 77, 917-922. 
 1 
 
 
Table S5. β-casein-derived peptides identified in milk fermented with Lactobacillus 
rhamnosus PRA331 whole cellsa. 
Sequenceb Observed 
mass (m/z)c 
Calculated 
massd 
Fragment Bioactivitye Reference 
  
 
   
LNVPGEIVE 485.2516 968.5179 f(6-14) ACEi Gobbetti et 
al., 2000 
NVPGEIVE 856.4256 855.4338 f(7-14) / / 
SITRIN 352.1995 702.4024 f(22-27) / / 
KKIEKF 396.7440 791.4905 f(28-33) / / 
KKIEKFQS(phospho)E 608.8120 1215.5900 f(28-36) / / 
DKIHPF 378.6905 755.3966 f(47-52) ACEi Gobbetti et 
al., 2000 
DKIHPFA 414.2081 826.4337 f(47-53) / / 
SLVYPFPGPIPN 1300.6991 1299.6863 f(57-68) / / 
LVYPFPGPIPN 1213.6643 1212.6543 f(58-68) / / 
VYPFPGPIPN 1100.5503 1099.5702 f(59-68) ACEi 
Antioxidant, 
Opioid 
Eisele et al., 
2013 
VYPFPGPIPNSLPQ 763.3809 1524.7977 f(59-72) / / 
YPFPGPIPN 1001.5294 1000.5018 f(60-68) ACEi 
DPPIV-inhibitor, 
Opioid 
Saito et al., 
2000 
SLPQNIPPL 978.5704 977.5546 f(69-77) / / 
SLPQNIPPLTQTPV 752.9436 1503.8297 f(69-82) / / 
SLPQNIPPLTQTPVVVPPFLQPEVM 1371.2513 2740.4874 f(69-93) / / 
QNIPPLTQTPV 604.3167 1206.6608 f(72-82) / / 
QNIPPLTQTPVVVPPF 874.0031 1745.9716 f(72-87) / / 
QNIPPLTQTPVVVPPFLQPE 738.7323 2213.2096 f(72-91) / / 
QNIPPLTQTPVVVPPFLQPEVM 815.4550 2443.3185 f(72-93) / / 
QNIPPLTQTPVVVPPFLQPEVMGVS 896.4847 2686.4404 f(69-96) / / 
NIPPLTQTPV 540.3031 1078.6023 f(73-82) ACEi Gobbetti et 
al., 2000 
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NIPPLTQTPVVVPPF 809.9655 1617.9131 f(73-87) / / 
NIPPLTQTPVVVPPFLQPEVM 1158.6488 2315.2599 f(73-93) / / 
TQTPVVVPPF 542.7930 1083.5965 f(78-87) / / 
TQTPVVVPPFL 599.3400 1196.6805 f(78-88) / / 
TQTPVVVPPFLQPE 776.4225 1550.8345 f(78-91) / / 
TQTPVVVPPFLQPEVM 891.4927 1780.9434 f(78-93) / / 
TQTPVVVPPFLQPEVMGVS 1013.0422 2024.0653 f(78-96) / / 
TQTPVVVPPFLQPEVMGVSKVKEAMAP 960.5032 2878.5337 f(78-104) / / 
QTPVVVPPFLQPE 725.8957 1449.7868 f(79-91) / / 
QTPVVVPPFLQPEVM 840.9478 1679.8957 f(79-93) / / 
PVVVPPFLQPE 611.3391 1220.6805 f(81-91) / / 
PVVVPPFLQPEVM 726.3960 1450.7894 f(81-93) / / 
VVPPFLQPE 1025.5809 1024.5593 f(83-91) / / 
VVPPFLQPEVM 1255.6756 1254.6682 f(83-93) / / 
VPPFLQPEVM 578.7956 1155.5998 f(84-93) / / 
PEVMGVSKVKEAMAPK 567.6384 1700.9074 f(90-105) / / 
VMGSKVKEA 349.8603 1046.5794 f(92-101) / / 
MAPKHKEMPFPKYPVEPF 725.0518 2172.0900 f(102-119) / / 
APKHKEMPFPKYPVEPF 681.3265 2041.0495 f(103-119) / / 
HKEMPFPKYPVEPF 582.6204 1744.8647 f(106-119) / / 
EMPFPKYPVEPF 740.8436 1479.7108 f(108-119) / / 
MPFPKYPVEP 602.8002 1203.5998 f(109-118) / / 
MPFPKYPVEPF 676.3260 1350.6682 f(109-119) / / 
MPFPKYPVEPFTE 791.3602 1580.7585 f(109-121) / / 
NLHLPLP 402.2289 802.4701 f(132-138) ACEi Kohmura et 
al., 1989 
NLHLPLPL 458.7739 915.5542 f(132-139) / / 
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NLHLPLPLL 515.3360 1028.6632 f(132-140) ACEi Robert et 
al., 2004 
NLHLPLPLLQ 579.3461 1156.6968 f(132-141) / / 
NLHLPLPLLQS 622.8557 1243.7288 f(132-142) / / 
NLHLPLPLLQSW 715.8693 1429.8082 f(132-143) / / 
LHLPLP 345.2061 688.4272 f(133-138) ACEi Kohmura et 
al., 1989 
LHLPLPL 401.7568 801.5112 f(133-139) ACEi Quiros et 
al., 2007 
LHLPLPLLQ 522.3205 1042.6539 f(133-141) / / 
LHLPLPLLQS 565.8474 1129.6859 f(133-142) / / 
LHLPLPLLQSW 658.8784 1315.7652 f(133-143) / / 
HLPLPL 345.2061 688.4272 f(134-139) / / 
HLPLPLLQSW 602.3478 1202.6812 f(134-143) / / 
LPLPLLQ 793.5105 792.5109 f(135-141) / / 
LPLPLLQSW 533.8107 1065.6223 f(135-143) / / 
WMHQPHQPLPPTVMFPPQ 723.3596 2167.0496 f(143-160) / / 
MHQPHQPLPPT 641.8081 1281.6288 f(144-154) / / 
MHQPHQPLPPTVM 504.9035 1511.7377 f(144-156) / / 
MHQPHQPLPPTVMFPPQ 661.3167 1980.9703 f(144-160) / / 
HQPHQPLPPT 576.2926 1150.5883 f(145-154) / / 
HQPHQPLPPTVM 461.2329 1380.6972 f(145-156) / / 
HQPHQPLPPTVMFPPQ 617.6437 1849.9298 f(145-160) / / 
FPPQSVL 787.4370 786.4272 f(157-163) / / 
SQSKVLPVPQ 541.8019 1081.6132 f(166-175) ACEi Hayes et al., 
2007 
QSKVLPVPQ 498.2873 994.5811 f(167-175) / / 
SKVLPVPQ 434.2558 866.5226 f(168-175) ACEi Yamamoto 
et al., 1994 
KVLPVPQ 780.4975 779.4905 f(169-175) ACEi Maeno et 
al., 1996 
VLPVPQ 652.3929 651.3956 f(170-175) / / 
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KAVPYPQ 401.7177 801.4385 f(176-182) / / 
KAVPYPQRDMPI 707.8531 1413.7438 f(176-186) / / 
RDMPIQAF 489.2344 976.4800 f(183-190) ACEi Yamamoto 
et al., 1994 
RDMPIQAFL 545.7702 1089.5641 f(183-191) / / 
RDMPIQAFLL 602.3312 1202.6481 f(183-192) / / 
LYQEPVL 861.4602 860.4644 f(192-198) / / 
YQEPVL 748.3849 747.3803 f(193-198) / / 
YQEPVLGPVRGPFP 778.4100 1554.8195 f(193-206) / / 
YQEPVLGPVRGPFPIIV 941.0424 1880.0560 f(193-209) Immunomodulator Boutrou et 
al., 2013 
QEPVLGPVRGPFP 686.8812 1391.7561 f(194-206) / / 
QEPVLGPVRGPFPIIV 859.5135 1716.9927 f(194-209) ACEi Lu et al., 
2016 
EPVLGPVRGPFP 632.8351 1263.6976 f(195-206) ACEi Hayes et al., 
2007 
EPVLGPVRGPFPIIV 795.4796 1588.9341 f(195-209) / / 
VLGPVRGPFPIIV 682.4057 1362.8388 f(197-209) / / 
LGPVRGPFPIIV 632.8861 1263.7703 f(198-209) / / 
GPVRGPFP 413.7160 825.4497 f(199-206) / / 
GPVRGPFPII 526.7979 1051.6179 f(199-208) / / 
GPVRGPFPIIV 576.3487 1150.6863 f(199-209) / / 
RGPFPIIV 449.7698 897.5436 f(202-209) / / 
aAbbreviations are: ACEi, angiotensin converting enzyme-inhibitory; DPPIV, dipeptidyl peptidase IV. 
bOne code letter was used for amino acid nomenclature. 
cThe observed mass is reported as [M+nH]n+. 
dThe calculated mass is in Da.  
ePotential bioactivities were achieved retrieved by searching peptide sequences against the BIOPEP and 
MBPDB databases (Minkiewicz et al., 2008; Nielsen et al., 2017).  
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Table S6. αS1-casein-derived peptides identified in milk fermented with Lactobacillus 
rhamnosus PRA331 whole cellsa. 
Sequenceb Observed 
mass (m/z)c 
Calculated 
massd 
Fragment Bioactivitye Reference 
RPKHPIKH 338.1924 1011.6090 f(1-8) / / 
RPKHPIKHQ 380.8905 1139.6676 f(1-9) ACEi Saito et al., 
2000 
RPKHPIKHQGLPQ 512.6139 1534.8844 f(1-13) / / 
RPKHPIKHQGLPQEVLN 498.5303 1990.1224 f(1-17) / / 
KHPIKHQ 444.2507 886.5137 f(3-9) / / 
GLPQEVL 755.4085 754.4298 f(10-16) / / 
GLPQEVLNE 499.7582 997.5080 f(10-18) / / 
ENLLRF 396.2095 790.4337 f(18-24) ACEi Boutrou et 
al., 2013 
FVAPFPE 806.4074 805.4010 f(24-30) / / 
FVAPFPEVF 1052.5164 1051.5379 f(24-32) ACEi Boutrou et 
al., 2013 
FVAPFPEVFGKE 683.8608 1365.6969 f(24-35) / / 
VAPFPE 659.3349 658.3326 f(25-30) / / 
VAPFPEVF 905.4909 904.4695 f(25-32) ACEi Boutrou et 
al., 2013 
VAPFPEVFGK 545.8130 1089.5859 f(25-34) / / 
VAPFPEVFGKE 610.3173 1218.6285 f(25-35) / / 
APFPEVF 806.4074 805.4010 f(26-32) / / 
APFPEVFGKE 560.7993 1119.5601 f(26-35) / / 
VFGKEKVN 460.7541 919.5127 f(31-38) / / 
KKYKVPQ 445.7685 889.5385 f(102-108) / / 
KYKVPQ 381.7245 761.4436 f(103-108) / / 
LEIVPN 684.3640 683.3854 f(109-114) / / 
S(phospho)AEELRH 461.1787 920.3753 f(115-121) / / 
S(phospho)AEELRHSM 570.2206 1138.4478 f(115-123) / / 
KEGIHAQ 391.6973 781.4082 f(124-130) / / 
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APSFSDIPNPIGSENSE 880.9123 1759.7901 f(176-192) / / 
FSDIPNPIGSE 588.2765 1174.5506 f(179-189) / / 
FSDIPNPIGSEN 645.3093 1288.5935 f(179-190) / / 
FSDIPNPIGSENSE 753.3208 1504.6682 f(179-192) / / 
IPNPIGSENSE 578.7531 1155.5408 f(182-192) / / 
aAbbreviation is: ACEi, angiotensin converting enzyme-inhibitory. 
bOne code letter was used for amino acid nomenclature. 
cThe observed mass is reported as [M+nH]n+. 
dThe calculated mass is in Da.  
ePotential bioactivities were achieved retrieved by searching peptide sequences against the BIOPEP and 
MBPDB databases (Minkiewicz et al., 2008; Nielsen et al., 2017).  
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Table S7. αS2-casein-derived peptides identified in milk fermented with Lactobacillus 
rhamnosus PRA331. 
Sequencea Observed 
mass (m/z)b 
Calculated 
massc 
Fragment Bioactivityd Reference 
SIIS(phospho)QETYK 574.7617 1147.5162 f(13-21) / / 
NAVPITPT 812.4463 811.4440 f(115-122) / / 
NAVPITPTLN 520.2697 1038.5710 f(115-124) / / 
NAVPITPTLNRE 662.8581 1323.7146 f(115-126) / / 
AVPITPT 698.4069 697.4010 f(116-122) / / 
AVPITPTLNRE 605.8419 1209.6717 f(116-126) / / 
MES(phospho)TEVFTK 576.2277 1150.4617 f(141-149) / / 
MES(phospho)TEVFTKK 640.2751 1278.5567 f(141-150) / / 
TKVIPYVRYL 417.9150 1250.7387 f(198-207) Antimicrobial Alvarez-
Ordóñez et 
al., 2013 
aOne code letter was used for amino acid nomenclature. 
bThe observed mass is reported as [M+nH]n+ 
cThe calculated mass is in Da.  
dPotential bioactivities were achieved retrieved by searching peptide sequences against the BIOPEP and 
MBPDB databases (Minkiewicz et al., 2008; Nielsen et al., 2017).  
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Table S8. κ-casein-derived peptides identified in milk fermented with Lactobacillus 
rhamnosus PRA331 whole cells. 
Sequencea Observed 
mass (m/z)b 
Calculated 
massc 
Fragment Bioactivityd Reference 
FSDKIA 340.6721 679.3541 f(18-23) / / 
KYIPIQY 462.7544 923.5116 f(24-30) / / 
KYIPIQYVL 568.8299 1135.6641 f(24-32) / / 
KYIPIQYVLS 612.3488 1222.6961 f(24-33) / / 
SRYPSYGLN 528.7591 1055.5036 f(33-41) / / 
RYPSYGLN 485.2353 968.4716 f(34-41) / / 
YYQQKPVAL 555.2734 1108.5917 f(42-50) / / 
YYQQKPVALIN 668.8605 1335.7187 f(42-52) / / 
YYQQKPVALINN 725.8975 1449.7616 f(42-53) / / 
QQKPVALINN 562.8214 1123.6349 f(44-53) / / 
QKPVALINN 498.7893 995.5764 f(45-53) / / 
QFLPYPYYAKPA 729.3794 1456.7391 f(54-65) / / 
FLPYPYYAKPA 665.3492 1328.6805 f(55-65) / / 
LPYPYYAKPA 591.8004 1181.6121 f(56-65) / / 
AVRSPA 300.6625 599.3391 f(66-71) / / 
AVRSPAQIL 477.7849 953.5658 f(66-74) / / 
AVRSPAQILQ 541.8019 1081.6244 f(66-75) / / 
ARHPHPHLS 351.1755 1050.5471 f(96-104) / / 
ARHPHPHLSFM 443.8816 1328.6560 f(96-106) / / 
EIPTIN 686.3505 685.3646 f(118-123) / / 
TIASGEPT 775.3862 774.3759 f(124-131) / / 
VATLEDS(phospho)PE 520.7108 1039.4111 f(143-152) / / 
VIESPPEIN 499.2569 996.5128 f(152-160) / / 
SPPEIN 328.6530 655.3167 f(155-160) / / 
 9 
 
SPPEINTVQ 492.7466 983.4924 f(155-163) / / 
aOne code letter was used for amino acid nomenclature. 
bThe observed mass is reported as [M+nH]n+. 
cThe calculated mass is in Da.  
dPotential bioactivities were achieved retrieved by searching peptide sequences against the BIOPEP and 
MBPDB databases (Minkiewicz et al., 2008; Nielsen et al., 2017).  
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